# ARTICLE IN PRESS

REVUE NEUROLOGIQUE XXX (2018) XXX-XXX



Available online at

**ScienceDirect** 

www.sciencedirect.com

Elsevier Masson France

EM consulte

www.em-consulte.com



### Letter to the Editor

# A case of acute posterior multifocal placoid pigment epitheliopathy with aseptic meningitis and cerebral infarction

# 1. Case report

A 24-year-old male with no medical history presented with a bilateral blurred vision that progressively worsened for three days without influenza-like illness. Fundoscopy showed multiple cream-colored placoid lesions (Fig. 1A). Optical coherence tomography revealed multiple hyperreflective lesions located in the outer nuclear layer and subfoveal photoreceptor layer disruption in both eyes (Fig. 2). Fluorescein angiogram showed early hypofluorescent lesions with a staining in the late sequence (Fig. 1B). Indocyanine green chorioangiography angiograms showed bilateral multiple hypofluorescent lesions in the early phase which persisted throughout the late phase (Fig. 3). Based on clinical features, the patient has been diagnosed with bilateral acute posterior multifocal placoid pigment epitheliopathy (APMPPE).

The next day, the patient was referred to the neurology department for a thunderbolt headache. He did not show any meningeal symptoms nor signs of focal lesion. Magnetic resonance imaging (MRI) showed no abnormalities. The analysis of the cerebrospinal fluid (CSF) revealed a lymphocyte count of 34.10<sup>6</sup>/L and a protein level of 0.46 g/L without any evidence of oligoclonal bands, a glucose level of 0.56 g/L. PCR for HSV, VZV and enterovirus in the CSF was reported negative. A lupus anticoagulant was detected in blood samples without any other immunological abnormalities. Borrelia burgdorferi serology, syphilis serology and tuberculin skin test were negative. Minor salivary gland biopsy and lung computed tomography were normal.

The diagnosis of APMPPE with aseptic meningitis was made. Intravenous methylprednisolone therapy was induced (3 g in 3 days) and followed by an oral steroid therapy of 1 mg/kg/day.

After two months, while decreasing steroid therapy, the patient presented with sudden-onset visual impairment, Weber's syndrome and impaired consciousness (NIHSS 20) requiring intensive care. Brain MRI showed mesencephalic and cerebral infarction in the territories of the posterior

cerebral artery and its paramedian branches, of the middle cerebral artery and of the anterior cerebral artery. Magnetic resonance angiography and contrast-enhanced MRI showed signs of vasculitis and meningitis (Fig. 1C). Cardiovascular investigation was normal. Intravenous methylprednisolone therapy and monthly cyclophosphamide infusion were induced, resulting in a partial improvement (NIHSS 9).

#### Discussion

APMPPE is an uncommon chorioretinopathy, affecting both women and men aged 20–50 years, characterized by multiple cream-colored placoid lesions located in the posterior pole leading to scotomas and photopsia [1]. Fluorescein angiography shows an early hypofluorescence and a late hyperfluorescence due to an inflammatory choriocapillaritis. The more frequent systemic sign is headache sometimes in thunderclap preceded by visual signs from few days to several months. Although rare, its neurological complications are: stroke, cerebral haemorrhage and seizure [2,3] due to vasculitis. The natural history of APMPPE is often good with recuperation of visual acuity but some symptoms may remain, and recurrences may occur.

The histopathological findings in cerebral arteries showed a segmental giant cells vasculopathy of meningeal arteries [4]. These findings are not reported in Vogt-Koyanagi-Harada disease which is a differential diagnosis. APMPPE may rarely be associated with sarcoidosis, syphilis, Lyme disease, adenovirus type 5 infection, tuberculosis, necrotizing vasculitis, vaccination for hepatitis B virus and varicella [5]. Investigations should research these associated diseases.

Headache and pleocytosis in CSF seem to be predictive factors of stroke [3], justifying a neurological care. When these predictive factors are present, an aggressive treatment like an immunosuppressive medication (azathioprine or cyclophosphamide) could be used. Presently, there is no consensus for therapeutic management of neurological involvement.




Fig. 1 – Ophthalmological investigation and Brain MRI. A: Right eye fundus color photography reveals multiple cream-colored placoid lesions. B: Fluorescein angiogram shows early hypofluorescence of the lesions (left) and later in the sequence, bright staining (right). C: Brain MRI: diffusion-weighted (left) image shows cerebral infarction of the posterior cerebral artery and its paramedian branches. MRA image (middle) shows an occlusion of the right posterior cerebral artery (arrow). Contrast-enhanced T2-FLAIR-weighted image (right) shows a temporo-occipital meningeal enhancement (arrow). Abbreviations. FLAIR: Fluid Attenuated Inversion Recovery. MRA: Magnetic Resonance Angiography.




Fig. 2 – Optical coherence tomography. Optical coherence tomography reveals hyperreflective lesions located in the outer nuclear layer (white arrows) and focal photoreceptor layer disruption (white arrows head).




Fig. 3 – Indocyanine green chorioangiography angiograms. Right eye ICG angiograms demonstrates multiple hypofluorescent lesions in the early phase (left) which persisted throughout late phase (right). Abbreviations. ICG: Indocyanine Green Chorioangiography.

Prospective studies will be useful to determine predictive factors and define guidelines for treatment.

## Disclosure of interest

The authors declare that they have no competing interest.

REFERENCES

- [1] Khaleeli Z, Tucker WR, Del Porto L, Virgo JD, Plant GT. Remember the retina: retinal disorders presenting to neurologists. Pract Neurol 2018;18:84–96. <a href="http://dx.doi.org/10.1136/practneurol-2016-001534">http://dx.doi.org/10.1136/practneurol-2016-001534</a>.
- [2] Thomas BC, Jacobi C, Korporal M, Becker MD, Wildemann B, Mackensen F. Ocular outcome and frequency of neurological manifestations in patients with acute posterior multifocal placoid pigment epitheliopathy (APMPPE). J Ophthalmic Inflamm Infect 2012;2:125–31. <a href="http://dx.doi.org/10.1007/s12348-012-0077-7">http://dx.doi.org/10.1007/s12348-012-0077-7</a>.
- [3] Brownlee WJ, Anderson NE, Sims J, Pereira JA. Neurological complications of acute multifocal placoid pigment epitheliopathy. J Clin Neurosci 2016. <a href="http://dx.doi.org/10.1016/j.jocn.2016.02.012">http://dx.doi.org/10.1016/j.jocn.2016.02.012</a>.
- [4] Tsang BK-T, Chauhan DS, Haward R, Whiteman I, Frayne J, McLean C. Fatal ischemic stroke complicating acute multifocal placoid pigment epitheliopathy: histopathological findings. J Neuro-Ophthalmol Off J North Am Neuro-Ophthalmol Soc 2014;34:10–5. <a href="http://dx.doi.org/10.1097/WNO.0b013e318294a4b0">http://dx.doi.org/10.1097/WNO.0b013e318294a4b0</a>.
- [5] Crawford CM, Igboeli O. A review of the inflammatory chorioretinopathies: the white dot syndromes. ISRN

Inflamm 2013;2013:783190. <a href="http://dx.doi.org/10.1155/2013/783190">http://dx.doi.org/10.1155/2013/783190</a>.

K. Bigaut<sup>a,\*</sup>

L. Kremer<sup>a,b</sup>

A. Hacquard<sup>d</sup>

B. Wolff<sup>e</sup>

N. Collongues<sup>a,b,c</sup>

J. De Seze<sup>a,b,c</sup>

<sup>a</sup>Service de neurologie, hôpitaux universitaires de Strasbourg, 67000 Strasbourg, France

bInserm U1434, centre d'investigation clinique, 67000 Strasbourg, France

<sup>c</sup>Inserm U1119, biopathologie de la myéline, neuroprotection et stratégies thérapeutiques, fédération de médecine translationnelle de Strasbourg, 67000 Strasbourg, France

<sup>d</sup>Service de neurologie, groupe hospitalier de la région de Mulhouse et Sud Alsace, 68100 Mulhouse, France

<sup>e</sup>Centre d'ophtalmologie de la maison rouge, 67000 Strasbourg, France

\*Corresponding author. E-mail address: kevin.bigaut@chru-strasbourg.fr (K. Bigaut)

> Received 3 April 2018 Received in revised form 19 June 2018 Accepted 20 June 2018 Available online xxx

https://doi.org/10.1016/j.neurol.2018.06.011 0035-3787/© 2019 Published by Elsevier Masson SAS.